CureVac grabs $213M in US IPO, adding to year's record pace

German biotech CureVac, a developer of vaccines and drugs for cancer, rare and infectious diseases, raised $213.3 million in an initial public offering in the U.S., pricing 13.33 million shares Thursday at $16 apiece.